Ligand Pharmaceuticals Inc (LGND)
105.78
-4.02
(-3.67%)
USD |
NASDAQ |
Oct 31, 16:00
105.70
-0.08
(-0.08%)
After-Hours: 20:00
Ligand Pharmaceuticals Cash from Financing (Quarterly): 9.491M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.491M |
| March 31, 2024 | 12.18M |
| December 31, 2023 | 5.315M |
| September 30, 2023 | 3.27M |
| June 30, 2023 | -67.76M |
| March 31, 2023 | -0.775M |
| December 31, 2022 | -5.298M |
| September 30, 2022 | -40.83M |
| June 30, 2022 | -59.44M |
| March 31, 2022 | -170.42M |
| December 31, 2021 | 4.164M |
| September 30, 2021 | -0.385M |
| June 30, 2021 | -49.90M |
| March 31, 2021 | -91.64M |
| December 31, 2020 | -27.53M |
| September 30, 2020 | -3.706M |
| June 30, 2020 | -0.005M |
| March 31, 2020 | -279.30M |
| December 31, 2019 | -83.69M |
| September 30, 2019 | -211.31M |
| June 30, 2019 | -37.59M |
| March 31, 2019 | -152.58M |
| December 31, 2018 | -347.08M |
| September 30, 2018 | 58.92M |
| June 30, 2018 | 613.53M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.224M |
| December 31, 2017 | -7.255M |
| September 30, 2017 | 1.404M |
| June 30, 2017 | -0.005M |
| March 31, 2017 | -1.667M |
| December 31, 2016 | -8.603M |
| September 30, 2016 | 1.629M |
| June 30, 2016 | 1.469M |
| March 31, 2016 | 0.511M |
| December 31, 2015 | 1.47M |
| September 30, 2015 | 1.46M |
| June 30, 2015 | 4.649M |
| March 31, 2015 | 0.781M |
| December 31, 2014 | -29.00M |
| September 30, 2014 | 162.32M |
| June 30, 2014 | -3.058M |
| March 31, 2014 | -0.241M |
| December 31, 2013 | -2.663M |
| September 30, 2013 | -2.048M |
| June 30, 2013 | -2.359M |
| March 31, 2013 | -9.388M |
| December 31, 2012 | 3.235M |
| September 30, 2012 | 1.439M |
| June 30, 2012 | 0.082M |
| March 31, 2012 | -0.84M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-279.30M
Minimum
Mar 2020
12.18M
Maximum
Mar 2024
-44.54M
Average
-5.298M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | -478.10M |
| Agios Pharmaceuticals Inc | 1.099M |
| ADMA Biologics Inc | -0.362M |
| Pieris Pharmaceuticals Inc | 0.00 |
| AnaptysBio Inc | 41.89M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.31M |
| Cash from Investing (Quarterly) | -54.76M |
| Free Cash Flow | -8.162M |
| Free Cash Flow Per Share (Quarterly) | 0.6199 |
| Free Cash Flow to Equity (Quarterly) | 11.18M |
| Free Cash Flow to Firm (Quarterly) | 11.18M |
| Free Cash Flow Yield | -0.43% |